NCT02426359View on ClinicalTrials.gov

Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

May 31, 2016

Conditions
Moderate to Severe Atopic Dermatitis
Interventions
DRUG

Q301 Cream

DRUG

Placebo

Trial Locations (7)

14203

Buffalo

27157

Winston-Salem

77845

College Station

78759

Austin

80220

Denver

08009

Berlin

08520

East Windsor

All Listed Sponsors
lead

Qurient Co., Ltd.

INDUSTRY

NCT02426359 - Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients | Biotech Hunter | Biotech Hunter